Jefferies upgrades UCB as selloff leaves Bimzelx risks priced in
Jefferies upgraded UCB to Hold from Underperform and raised its price target to €220 from €212 after UCB’s first-half results showed pricing headwinds for psoriasis drug Bimzelx. The broker cited a more balanced risk-reward, raised 2026-27 revenue and EBITDA estimates, and forecast 2026-28 revenue of €8.63-€10.58B.
How this was made
The 30-second read
Why it matters
Jefferies’ upgrade and higher revenue/EBITDA estimates provide a valuation and earnings-support narrative, but the note reiterates that Bimzelx pricing reductions continue and that competitor immunology readouts over the next 12 to 24 months are a key downside driver.
Market read
A broker upgrade with explicit PT and estimate revisions can move sentiment and positioning, but the underlying thesis still centers on ongoing Bimzelx pricing pressure and future competitive readouts.
What to watch
Jefferies attributes EBITDA beat partly to an accrual adjustment, so traders may discount near-term earnings optics and focus on realized pricing and prescription conversion trends.
Background
UCB’s psoriasis drug Bimzelx has faced pricing headwinds after first-half results, contributing to a de-rating versus Jefferies’ prior valuation framework.
Ticker impact
Jefferies upgraded UCB to Hold from Underperform and raised its price target to €220 after first-half results showed Bimzelx pricing headwinds.
Near term, modest support from the upgrade and raised PT, but upside may be capped by continued Bimzelx price reductions and competitor readout risk.
The article is a broker action with explicit PT and estimate changes, yet it also emphasizes ongoing Bimzelx pricing pressure and second-half price reductions, limiting conviction.
Market effects
Signals continued scrutiny of psoriasis immunology pricing dynamics and competitive readout timing for large-cap biotech.
Primarily impacts European biotech sentiment via UCB’s de-rating narrative and broker re-rating.
Limited spillover beyond immunology peers unless competitor readouts or pricing trends broaden.
Counterpoint
The upgrade may be more about valuation balance than fundamental re-acceleration, since the text still highlights further Bimzelx price reductions in the second half.
Key entities
- public_companyUCB
Belgian biotech subject of the Jefferies upgrade, with Bimzelx pricing headwinds and revised 2026-2028 estimates.
- productBimzelx
Psoriasis drug at the center of the pricing headwinds and scenario modeling.
- productBriviact
Antiseizure drug cited as a strength driving Jefferies’ revenue estimate increases.
- productCimzia
Immunology drug referenced for potential erosion in Jefferies’ scenarios.
